BiotechTube

Vandetanib (SAR390530) + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Differentiated Thyroid Cancer

Conditions

Differentiated Thyroid Cancer

Trial Timeline

Sep 17, 2013 → Jan 22, 2022

NCT ID
NCT01876784

About Vandetanib (SAR390530) + Placebo

Vandetanib (SAR390530) + Placebo is a phase 3 stage product being developed by Sanofi for Differentiated Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01876784. Target conditions include Differentiated Thyroid Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01876784Phase 3Completed

Competing Products

20 competing products in Differentiated Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
33
Abemaciclib + PlaceboEli LillyPhase 3
77
Lenvatinib + PlaceboEisaiPhase 3
77
LenvatinibEisaiPre-clinical
23
LenvatinibEisaiPhase 2
52
LENVATINIBEisaiPhase 2
52
Selpercatinib MonotherapyEli LillyPhase 2
52
Selumetinib + Placebo + Radioactive Iodine TherapyAstraZenecaPhase 3
77
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
52
PembrolizumabMerckPhase 2
52
sunitinib + everolimus + chemotherapies recommended in franceNovartisPre-clinical
23
Everolimus + SorafenibNovartisPhase 2
52
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placeboNovartisPhase 3
77
PDR001NovartisPhase 2
52
Everolimus (Afinitor®)NovartisPhase 2
52
Sacituzumab govitecanGilead SciencesPhase 2
51
sunitinibPfizerApproved
84
Thyrogen (thyrotropin alfa for injection)SanofiPhase 3
76
CabazitaxelSanofiPhase 2
51
Larotrectinib monotherapyBayerPhase 2
49

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84